![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » U.S. DEPARTMENT OF HOMELAND SECURITY CERTIFIES BIOTHRAX (ANTHRAX VACCINE ADSORBED) AS AN APPROVED PRODUCT FOR HOMELAND SECURITY
U.S. DEPARTMENT OF HOMELAND SECURITY CERTIFIES BIOTHRAX (ANTHRAX VACCINE ADSORBED) AS AN APPROVED PRODUCT FOR HOMELAND SECURITY
Emergent BioSolutions Inc., a privately held biopharmaceutical company, announced that the United States Department of Homeland Security (DHS) has granted the company's application for designation and certification of BioThrax (Anthrax Vaccine Adsorbed) as a "qualified anti-terrorism technology" under the "Support Anti- Terrorism by Fostering Effective Technology Act" (SAFETY Act). BioThrax, the only FDA-approved vaccine for the prevention of anthrax infection, is the first vaccine to be granted such SAFETY Act coverage. Drug Newswire (http://www.drugnewswire.com/5281/)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct